{"id":"https://openalex.org/W1994597382","doi":"https://doi.org/10.1016/s1470-2045(12)70419-9","title":"Trametinib for patients with advanced melanoma","display_name":"Trametinib for patients with advanced melanoma","publication_year":2012,"publication_date":"2012-09-28","ids":{"openalex":"https://openalex.org/W1994597382","doi":"https://doi.org/10.1016/s1470-2045(12)70419-9","mag":"1994597382","pmid":"https://pubmed.ncbi.nlm.nih.gov/23026823"},"language":"en","primary_location":{"id":"doi:10.1016/s1470-2045(12)70419-9","doi":"https://doi.org/10.1016/s1470-2045(12)70419-9","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1470-2045(12)70419-9","pdf_url":null,"source":{"id":"https://openalex.org/S116900674","display_name":"The Lancet Oncology","issn_l":"1470-2045","issn":["1470-2045","1474-5488"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet Oncology","raw_type":"journal-article"},"volume":null,"type":"letter","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067046418","display_name":"Shigeo Masuda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1307098950","display_name":"Salk Institute for Biological Studies","ror":"https://ror.org/03xez1567","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1307098950"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Shigeo Masuda","raw_affiliation_strings":["Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA","institution_ids":["https://openalex.org/I1307098950"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050690657","display_name":"Juan Carlos Izpis\u00faa Belmonte","orcid":"https://orcid.org/0000-0003-0557-8875","observed_orcids":["https://orcid.org/0000-0003-0557-8875"]},"institutions":[{"id":"https://openalex.org/I1307098950","display_name":"Salk Institute for Biological Studies","ror":"https://ror.org/03xez1567","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1307098950"]},{"id":"https://openalex.org/I4210138155","display_name":"Center of Regenerative Medicine in Barcelona","ror":"https://ror.org/03q0p7c86","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210138155","https://openalex.org/I4387153040"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"Juan Carlos Izpisua Belmonte","raw_affiliation_strings":["Center for Regenerative Medicine in Barcelona, Barcelona, Spain","Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Regenerative Medicine in Barcelona, Barcelona, Spain","institution_ids":["https://openalex.org/I4210138155"]},{"raw_affiliation_string":"Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA","institution_ids":["https://openalex.org/I1307098950"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5067046418"],"corresponding_institution_ids":["https://openalex.org/I1307098950"],"apc_list":{"value":7280,"currency":"USD","value_usd":7280},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"13","issue":"10","first_page":"e409","last_page":"e409"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":0.9879999756813049},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.9860000014305115},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.9359999895095825},{"id":"https://openalex.org/keywords/braf-mutant-melanoma","display_name":"BRAF-mutant melanoma","score":0.9100000262260437},{"id":"https://openalex.org/keywords/hepatocyte-growth-factor","display_name":"hepatocyte growth factor","score":0.7279999852180481},{"id":"https://openalex.org/keywords/raf-inhibitor-resistance","display_name":"RAF inhibitor resistance","score":0.7749999761581421},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.7979999780654907},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.703000009059906},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.3799999952316284},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.503000020980835},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.4359999895095825},{"id":"https://openalex.org/keywords/driver-mutations","display_name":"driver mutations","score":0.4659999907016754}],"concepts":[{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.9640992283821106},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.729195237159729},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.7083747386932373},{"id":"https://openalex.org/C83867959","wikidata":"https://www.wikidata.org/wiki/Q371467","display_name":"Scopus","level":3,"score":0.5545837879180908},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5442651510238647},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.4764328896999359},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4624713957309723},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.3992058336734772},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36932820081710815},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.33538615703582764},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3293308615684509},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.2918592095375061},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24981722235679626},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.20056045055389404},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.11828339099884033},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09904474020004272},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.08075591921806335},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011744","descriptor_name":"Pyrimidinones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014604","descriptor_name":"Uveal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D048369","descriptor_name":"MAP Kinase Kinase 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D048370","descriptor_name":"MAP Kinase Kinase 2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/s1470-2045(12)70419-9","doi":"https://doi.org/10.1016/s1470-2045(12)70419-9","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1470-2045(12)70419-9","pdf_url":null,"source":{"id":"https://openalex.org/S116900674","display_name":"The Lancet Oncology","issn_l":"1470-2045","issn":["1470-2045","1474-5488"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet Oncology","raw_type":"journal-article"},{"id":"pmid:23026823","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23026823","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet. Oncology","raw_type":"Letter"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.8199999928474426,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W1988379285","https://openalex.org/W1999025555","https://openalex.org/W2035000040","https://openalex.org/W2055624262","https://openalex.org/W2134471382"],"related_works":["https://openalex.org/W2026299932","https://openalex.org/W2104148147","https://openalex.org/W1634119801","https://openalex.org/W2945871854","https://openalex.org/W1988379285","https://openalex.org/W2125845533","https://openalex.org/W2144096834","https://openalex.org/W2165046781","https://openalex.org/W7131390539","https://openalex.org/W92627887"],"abstract_inverted_index":null,"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}